泰格醫藥(300347.SZ):預計2024年淨利潤同比下降72%-81%
格隆匯1月24日丨泰格醫藥(300347.SZ)公佈,預計2024年營業收入600,000萬元–700,000萬元,比上年同期下降19%–5%,淨利潤38,000萬元–57,000萬元,比上年同期下降81%–72%,扣非淨利潤83,000萬元–100,000萬元,比上年同期下降44%–32%。
2024年公司持有的非流動金融資產(主要包括非上市公司股權投資、上市公司股份和醫藥基金)產生的投資收益和公允價值變動損益同比變化較大,且公允價值發生較大減少。公司通過密切關注行業趨勢及項目的融資、財務及研發狀況等,定期實施風險篩查,識別風險項目,並進行相應的公允價值調整。報吿期內,歸屬於上市公司股東的非經常性損益為人民幣-45,000萬元至人民幣-43,000萬元;上年同期歸屬於上市公司股東的非經常性損益為人民幣54,760.79萬元,非經常性損益減少人民幣99,760.79萬元至人民幣97,760.79萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.